EMA published a concept paper on predictive biomarker-based assay development and companion diagnostics in the context of drug development and lifecycle. The paper argues that “more personalized medicines are being developed and approved” and that using a closely-knit development program linking medicinal product development, medical device regulation, and clinical trials to generate evidence required to support validation of the diagnostic is essential.
[/membership][membership level=”0,4″][The content continues for paid members only.]
Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership]
